Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis.
Endothelial activation is a key feature of multiple sclerosis (MS) pathogenesis. It is modulated by interferon beta-1b (IFNB-1b) treatment in relapsing-remitting MS (RRMS) patients. This particular pharmacodynamic effect still has to be proven in primary progressive MS (PPMS). In the current study, serum concentrations of soluble vascular cell adhesion molecule-1 (sVCAM-1) and sE-selectin were analyzed longitudinally in 18 PPMS patients before, during and after 12 months of treatment with IFNB-1b. During drug therapy there was a significant early and sustained increase of sVCAM-1 (overall P < 0.0001). Flu-like symptoms induced by IFNB-1b and also concomitant infections were associated with higher sVCAM-1 levels. Neutralizing antibodies to IFNB-1b were associated with lower sVCAM-1 levels. In conclusion, IFNB-1b modulates the adhesion cascade in patients with PPMS in a similar way it does in RRMS. Nevertheless, a clinical effect of IFNB in PPMS still has to be proven in a randomized controlled clinical trial.
Bitsch
A
A
Neurologische Klinik, Ruppiner Kliniken GmbH, Neuruppin, Germany. a.bitsch@ruppiner-kliniken.de
Bahner
D
D
Wachter
C
C
Elitok
E
E
Bogumil
T
T
Dressel
A
A
Polak
T
T
Tumani
H
H
Weber
F
F
Poser
S
S
Kitze
B
B
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000494:pharmacology*; D000293:Adolescent; D000328:Adult; D002448:Cell Adhesion / Q000187:drug effects; D042783:Endothelial Cells / Q000502:physiology; D005260:Female; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000009:adverse effects / Q000276:immunology* / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology*; D019010:Vascular Cell Adhesion Molecule-1 / Q000097:blood*
D000276:Adjuvants, Immunologic; D019010:Vascular Cell Adhesion Molecule-1; D000068576:Interferon beta-1b; D016899:Interferon-beta